Monopar Therapeutics Inc. (MNPR)
- Previous Close
0.6280 - Open
0.6300 - Bid 0.6187 x 100
- Ask 0.6969 x 100
- Day's Range
0.6300 - 0.6645 - 52 Week Range
0.2740 - 1.7500 - Volume
34,550 - Avg. Volume
5,414,119 - Market Cap (intraday)
11.489M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
www.monopartx.comRecent News: MNPR
Performance Overview: MNPR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNPR
Valuation Measures
Market Cap
11.49M
Enterprise Value
4.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.66%
Return on Equity (ttm)
-107.19%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.4M
Diluted EPS (ttm)
-0.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
7.27M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.01M